chevron_leftBack
As of 15 June 2026, Taysha Gene Therapies, Inc. has a market cap of $1.8B USD, ranking #7551 globally and #1767 in the United States.
It ranks #611 in the Healthcare sector, and #115 in the Biotechnology industry.
Key Stats
Market Cap
$1.8BUSD
Enterprise Value
$1.53BUSD
Revenue (TTM)
$9.77MUSD
EBITDA (TTM)
-$109.35MUSD
Net Income (TTM)
-$109.0MUSD
PS Ratio
182.3
PB Ratio
7.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Sean Nolan
open_in_new
Employees
99
Founded
2019
IPO
24 Sep 2020
Website
tayshagtx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.5% | -6.7% | 54% | 40% | 26% | 248% |
News
Loading...
TSHA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TSHA
Taysha Gene Therapies Inc Ordinary Shares
ISIN: US8776191061
Shares Out.:
Shares Outstanding:
287.361M1
Shares Float:
237.991M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
6.27 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
10K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
9K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
1K%
|
-
|
|
NYSE: IQV
|
$26.3B
1K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
1K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
906%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
3K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
2K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
2K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
2K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
1K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
1K%
|
-
|
chevron_leftBack